vimarsana.com
Home
Live Updates
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates : vimarsana.com
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
31.05.2023 - – TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon IL-2 β/γ administered every 3 weeks was ... Seite 1
Related Keywords
Copenhagen ,
Køavn ,
Denmark ,
Ascendis Pharma ,
Jan Mikkelsen ,
Stina Singel ,
Webcast Of Ascendi Oncology Program ,
Company Oncology ,
Head Of Clinical Development ,
Ascendi Oncology Program Update ,
Executive Vice President ,
Clinical Development ,
vimarsana.com © 2020. All Rights Reserved.